Utilisation of dense gas technology for the development of controlled release active pharmaceutical ingredients (API) delivery systems. The aim of this project is to develop an orally administered drug formulation for the treatment of irritable bowel syndrome and other diseases of the colon. Irritable bowel syndrome is a debilitating condition and the cost to society is similar to that of asthma. As such, the project has the potential to have a major impact on society.